Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered question first ministerially corrected answering member label previous answer version answering member constituency answering member printed answering member label
tabling member	label

Search

1132403

registered interest
date	17/06/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Lumacaftor/ivacaftor
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what contingency plans his Department has put in place in the event that Vertex declines NHS England’s latest offer for the supply of Orkambi.
tabling member constituency	Birmingham, Selly Oak
tabling member printed	Steve McCabe
uin	265417
answer	answer is ministerial correction date of answer 20/06/2019 answer text <p>NHS England is leading the negotiations with Vertex and has made a revised and improved offer to Vertex that would provide immediate funding for Orkambi, and Symkevi in advance of assessment by the National Institute for Health and Care Excellence (NICE), and expanded access to Kalydeco which is already funded on the National Health Service for certain patients.</p><p>The Government fully supports NICE and NHS England in seeking to ensure access for patients to effective and innovative medicines at a price that represents value to the NHS, and it is not for Ministers to intervene in this process. The Department’s approach remains to urge Vertex to accept NHS England’s generous offer, but we will explore other options to ensure patients can access treatments as soon as possible.</p> answering member constituency South Ribble answering member printed Seema Kennedy grouped question UIN 265418 question first answered 20/06/2019 09:33:36 answering member 4455 label Biography information for Seema Kennedy
tabling member	298 label Biography information for Steve McCabe

1132404

registered interest
date	17/06/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Lumacaftor/ivacaftor: Clinical Trials
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential merits of launching a large scale clinical trial of the generic version of Orkambi.
tabling member constituency	Birmingham, Selly Oak
tabling member printed	Steve McCabe
uin	265418
answer	answer is ministerial correction date of answer 20/06/2019 answer text <p>NHS England is leading the negotiations with Vertex and has made a revised and improved offer to Vertex that would provide immediate funding for Orkambi, and Symkevi in advance of assessment by the National Institute for Health and Care Excellence (NICE), and expanded access to Kalydeco which is already funded on the National Health Service for certain patients.</p><p>The Government fully supports NICE and NHS England in seeking to ensure access for patients to effective and innovative medicines at a price that represents value to the NHS, and it is not for Ministers to intervene in this process. The Department’s approach remains to urge Vertex to accept NHS England’s generous offer, but we will explore other options to ensure patients can access treatments as soon as possible.</p> answering member constituency South Ribble answering member printed Seema Kennedy grouped question UIN 265417 question first answered 20/06/2019 09:33:36 answering member 4455 label Biography information for Seema Kennedy
tabling member	298 label Biography information for Steve McCabe

1132424

registered interest
date	17/06/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Skin Cancer
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what steps he is taking to reduce the number of cases of melanoma.
tabling member constituency	East Londonderry
tabling member printed	Mr Gregory Campbell
uin	265456
answer	answer is ministerial correction date of answer 20/06/2019 answer text <p>On 16 June 2014, a local pilot campaign launched in Devon, Cornwall and Somerset to raise awareness of the signs of skin cancer. It encouraged people to tell their doctor if they noticed any unusual or persistent changes to their skin. It ran until 27 July 2014 and included adverts in the press and on local radio, as well as some direct mail to the target group.</p><p> </p><p>Skin Cancer awareness month is an annual awareness campaign that takes place every May. The campaign aims to raise awareness of the dangers of unprotected sun exposure and educate the public about the ways to help prevent skin cancer.</p><p>The Sunbeds (Regulation) Act 2010 came into force in April 2011 in England and Wales to prohibit under-18s from using sunbeds.</p><p> </p><p>Public Health England (PHE) contributed to the revision of the World Health Organization publication “Artificial tanning devices - Public health interventions to manage sunbeds”, which was published in 2017. PHE advises that sunbeds emit ultraviolet radiation, which can cause tanning and sunburn.</p><p> </p><p><strong> </strong></p><p><strong> </strong></p> answering member constituency South Ribble answering member printed Seema Kennedy question first answered 20/06/2019 14:14:40 answering member 4455 label Biography information for Seema Kennedy
tabling member	1409 label Biography information for Mr Gregory Campbell

1132431

registered interest
date	17/06/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Pharmacy Integration Fund
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what the current balance of the pharmacy integration fund is; and what initiatives have been supported by that fund since its inception.
tabling member constituency	Rother Valley
tabling member printed	Sir Kevin Barron
uin	265429
answer	answer is ministerial correction date of answer 20/06/2019 answer text <p>NHS England and NHS Improvement are awaiting the completion of the annual audit of its accounts, therefore no final figure is currently available for the balance of the Pharmacy Integration Fund (PhIF). The PhIF has supported a range of initiatives, including:</p><p>- Recruitment and training of pharmacists to support integrated urgent care services, offering patients and care staff direct access to clinical advice and care from pharmacists;</p><p>- Putting pharmacists and pharmacy technicians into the multi-disciplinary teams delivering enhanced health in care homes, to support medicines optimisation for people who live in care homes;</p><p>- The development of an urgent medicines supply service. This connects people who contact NHS 111 for urgent access to medicines with local community pharmacies who are able to dispense, and redirects demand out of general practitioner out of hours services, and/or accident and emergency departments;</p><p>- The piloting of a minor illness service, which enables people who contact NHS 111 to get urgent care and advice from a local community pharmacy for a range of common illness complaints; and</p><p>- Providing leadership training for the profession to support them to work effectively with their partners in the emerging integrated care systems, with a focus on delivering the range of benefits of medicines optimisation.</p><p>Further information can be found on NHS England’s website and accessed via the following link:</p><p><a href="https://www.england.nhs.uk/primary-care/pharmacy/pharmacy-integration-fund/" target="_blank">https://www.england.nhs.uk/primary-care/pharmacy/pharmacy-integration-fund/</a></p> answering member constituency South Ribble answering member printed Seema Kennedy question first answered 20/06/2019 14:13:14 answering member 4455 label Biography information for Seema Kennedy
tabling member	392 label Biography information for Sir Kevin Barron

1132599

registered interest
date	17/06/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Out-patients: Attendance
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what recent assessment he has made of the cost to the public purse of missed (a) GP and (b) hospital appointments.
tabling member constituency	Tewkesbury
tabling member printed	Mr Laurence Robertson
uin	265416
answer	answer is ministerial correction date of answer 20/06/2019 answer text <p>Information surrounding the cost of missed general practitioner and hospital appointments is not collected or held centrally.</p> answering member constituency South Ribble answering member printed Seema Kennedy question first answered 20/06/2019 09:32:08 answering member 4455 label Biography information for Seema Kennedy
tabling member	253 label Biography information for Mr Laurence Robertson

1132220

registered interest
date	14/06/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Obesity: Children
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what the timeframe is for the publication of the report by Professor Dame Sally Davies on a potential tax on unhealthy food to tackle childhood obesity.
tabling member constituency	Leicester East
tabling member printed	Keith Vaz
uin	264721
answer	answer is ministerial correction date of answer 24/06/2019 answer text <p>The Chief Medical Officer’s review of potential actions to help meet our ambition of halving childhood obesity by 2030 is due for publication in September.</p> answering member constituency South Ribble answering member printed Seema Kennedy question first answered 24/06/2019 16:47:44 answering member 4455 label Biography information for Seema Kennedy
tabling member	338 label Biography information for Keith Vaz

1131994

registered interest
date	13/06/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Ovarian Cancer: Contraceptives
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what recent discussions he has had with the Royal College of Nursing on use of the contraceptive pill to reduce the chances of ovarian cancer.
tabling member constituency	Strangford
tabling member printed	Jim Shannon
uin	264404
answer	answer is ministerial correction date of answer 21/06/2019 answer text <p>No such discussions have taken place. Any treatment available on the National Health Service is in line with the appropriate clinical guidelines from the National Institute for Health and Care Excellence.</p> answering member constituency South Ribble answering member printed Seema Kennedy question first answered 21/06/2019 10:32:36 answering member 4455 label Biography information for Seema Kennedy
tabling member	4131 label Biography information for Jim Shannon

1132025

registered interest
date	13/06/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Cannabis: Medical Treatments
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, how and by whom medical cannabis was produced in the UK before its legalisation.
tabling member constituency	Central Ayrshire
tabling member printed	Dr Philippa Whitford
uin	264425
answer	answer is ministerial correction date of answer 18/06/2019 answer text <p>Prior to the change of the law on 1 November 2018, only cannabis-based products that had been given a marketing authorisation (product licence) by the medicines regulators, the Medicines and Healthcare products Regulatory Agency (MHRA) or European Medicines Agency could be prescribed. Before issuing a marketing authorisation the MHRA accesses all the available evidence on efficacy and safety arising out of pre-clinical research and clinical trials and evidence and information supplied by the manufacturer. The regulators also inspect the factory where the medicine is to be made, to make sure that supplies will be of a uniformly and consistently high standard.</p><p> </p><p>The following cannabis-based products and related products received a marketing authorisation in the United Kingdom/European Union before 1 November 2018:</p><p> </p><p>- Sativex - (produced by GW Pharmaceuticals) containing tetrahydrocannabinol (THC) and cannabidiol - holds a licence for spasticity in multiple sclerosis; and</p><p>- Nabilone - (multiple manufacturers) which contains a synthetic, non-natural cannabinoid which mimics THC, holds a marketing authorisation for nausea and vomiting caused by chemotherapy.</p><p> </p><p>In addition, Epidiolex (also produced by GW Pharmaceuticals from cannabis) for two severe forms of intractable epilepsy (Lennox-Gastaut Syndrome or Dravet Syndrome), is currently being considered for a marketing authorisation by the European Medicines Agency.</p><p> </p><p>The change in the law allows the prescription, by specialist doctors on the General Medical Council’s Specialist Register, of cannabis-based products that have not been through this rigorous process but that meet certain quality standards in cases where all licensed products have been considered and discounted and it is in the best interest of the patient. It also makes</p><p>it easier and will incentivise further research into the potential health benefits of cannabis-based products and the development of further licensed products for more routine use in the health service.</p> answering member constituency South Ribble answering member printed Seema Kennedy question first answered 18/06/2019 16:31:54 answering member 4455 label Biography information for Seema Kennedy
tabling member	4385 label Biography information for Dr Philippa Whitford

1132034

registered interest
date	13/06/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Primary Care Networks: Rural Areas
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, whether his Department has carried out a rural proofing review of the implementation of primary care networks.
tabling member constituency	Newton Abbot
tabling member printed	Anne Marie Morris
uin	264405
answer	answer is ministerial correction date of answer 21/06/2019 answer text <p>Recognising the specific circumstances faced by some rural practices, there are additional flexibilities. NHS England has explicitly allowed rurality as an exception for meeting the definition of a Primary Care Networks. As set out in the Network Contract Direct Enhanced Service (DES) (under paragraph 3.2) commissioners may waiver the 30,000 minimum population “where a PCN serves a natural community which has a low population density across a large rural and remote area”. Further information is available at the following link:</p><p><a href="https://www.england.nhs.uk/wp-content/uploads/2019/03/network-contract-des-specification-2019-20-v1.pdf" target="_blank">https://www.england.nhs.uk/wp-content/uploads/2019/03/network-contract-des-specification-2019-20-v1.pdf</a></p><p> </p><p> </p><p><strong> </strong></p><p><strong> </strong></p> answering member constituency South Ribble answering member printed Seema Kennedy question first answered 21/06/2019 11:16:38 answering member 4455 label Biography information for Seema Kennedy
tabling member	4249 label Biography information for Anne Marie Morris

1132035

registered interest
date	13/06/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Primary Care Networks
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what the requirements for primary care networks to engage with the local community will be.
tabling member constituency	Newton Abbot
tabling member printed	Anne Marie Morris
uin	264406
answer	answer is ministerial correction date of answer 18/06/2019 answer text <p><ins class="ministerial"> <p><ins class="ministerial">Primary Care Networks (PCNs) are a new way for primary and community service organisations to work together. For PCNs to be successful they will need to work in partnership with local people and the communities they serve. Legal duties which currently apply to NHS service providers - including general practitioner practices - and commissioners around engagement and consultation will continue to be valid for PCNs.</ins></p></ins></p><p><del class="ministerial">NHS England and NHS Improvement, together with the National Institute for Health and Care Excellence, is developing a ’commercial framework’ setting out the parameters for the commercial approach for medicines in the health service in England.</del></p><p><del class="ministerial">The commercial framework will support a single, transparent, robust and integrated pricing and market access process, and is being tested with and informed through consultation with stakeholders including the Association of the British Pharmaceutical Industry.</del></p><p><del class="ministerial">In preparation for public consultation in the coming months, NHS England is actively engaging with industry trade bodies and health system partners, in the first instance, to outline progress on the development of the commercial framework. The consultation on the draft framework is anticipated to be launched in Quarter 3 2019 with consultation events to be held in Manchester and London, and implementation of the commercial framework is expected to follow.</del></p> answering member constituency South Ribble answering member printed Seema Kennedy question first answered 18/06/2019 16:34:05 question first ministerially corrected 19/06/2019 08:36:30 answering member 4455 label Biography information for Seema Kennedy previous answer version 123829 answering member constituency South Ribble answering member printed Seema Kennedy answering member 4455 label Biography information for Seema Kennedy
tabling member	4249 label Biography information for Anne Marie Morris